Skip to content

What’s New in Caring for People Living with HIV Infection? An Update for the Pharmacist

Live Webinar
March 10, 2022 | 1:00 PM - 2:00 PM EST

This educational session is designed to meet the educational needs of pharmacists working as part of the healthcare team to develop appropriate treatment plans for patients with Human Immunodeficiency Virus (HIV).

Learning Objectives

Upon completion of this activity, the participant will be able to:

  • Discuss selection of initial antiretroviral therapy for an individual patient, including dosing, adverse effects, food requirements, and patient counseling points
  • Identify the role of recently approved agents in the treatment of HIV infection, including long acting cabotegravir plus rilpivirine
  • Plan how to incorporate counseling for people living with HIV infection into a variety of pharmacy practice settings


Linda Spooner, PharmD, BCPS, FASHP, FCCP is a Professor of Pharmacy Practice at Massachusetts School of Pharmacy and Health Sciences - Worcester/Manchester in Worcester, Massachusetts. Dr. Spooner earned her Bachelor of Science degree in Pharmacy from the University of Connecticut, and her Doctor of Pharmacy degree from the University of Oklahoma Health Sciences Center. Over the past 21 years her practice has focused on infectious diseases with an emphasis on HIV and viral hepatitis. She maintains an inpatient practice at Saint Vincent Hospital, where her students rotate on teams providing care for patients on the general medical floor. She also participates in a weekly clinic caring for people living with HIV and viral hepatitis. At MCPHS, her teaching focuses on infectious diseases, and she coordinates an elective course for second-year pharmacy students entitled “Pharmacotherapy of HIV and Viral Hepatitis”.

There is no fee to attend this activity. Registration is required to earn ACPE credit. This webinar will be hosted on Zoom.


Contact Hour: 1.0
Universal Activity Number:  0026-0000-22-103-L02-P | knowledge-based
Topic Designator: HIV/AIDS


ACPE logo

Massachusetts College of Pharmacy and Health Sciences is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. MCPHS designates this educational activity for a total of 1.0 contact hours (.10 CEUs).

Requirements for Credit

Partial credit will not be awarded. To claim credit participants must log into their profile on MCPHS CE portal and insert the specific activity code for this webinar in order to access and complete the evaluation. CE credit will be automatically uploaded to CPE Monitor upon completion of the evaluation and posted to the participant’s NABP account within 72 hours.

Attendance will be verified. Credit will not be issued to participants who join the meeting more than 15 minutes after the start of the meeting or to those who depart early. Credit cannot be awarded to individuals who complete the activity evaluation more than 60 days post activity.


All participants will have the opportunity to review the educational session and speakers, and to identify future educational needs.

Statement of Disclosure

Massachusetts College of Pharmacy and Health Sciences adheres to the ACPE Standards for Integrity and Independence in Continuing Education. It is the policy of MCPHS that the speakers and planning committee members disclose all financial relationships with ineligible companies within the last 24 months, and that relevant conflicts of interest are mitigated. Speakers will disclose any off-label/unapproved use of drugs or devices during their presentation.

Linda Spooner has attended a one day advisory board meeting for TheraTechnologies. Conflicts have been mitigated through a peer review process per MCPHS Policy.

Massachusetts College of Pharmacy and Health Sciences Continuing Education staff members hold no financial relationships with ineligible companies, related to the content of this presentation.

No funding from industry provided for this event. No exhibitors will be present.

Off-label/investigational uses of a lenacapavir will be discussed. This agent is on a clinical hold at this time (1/2022).